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ABSTRACT In the present study, we describe the effects of lycopene on the symptoms of streptozotocin (STZ)–induced
diabetes in rats. Lycopene at the dose of 2.5 mg/kg body weight (bw) per day was orally administered to STZ-induced diabetic
rats for a period of 7 days after onset of diabetes. At the same time, food–water intake and body weight change were recorded
daily. Upon sacrifice, biochemical parameters, such as the serum glucose, insulin, total cholesterol (TC), triglyceride (TG),
alanine aminotransferase (ALT), and aspartate aminotransferase (AST), were measured in all experimental groups. Admin-
istration of lycopene at the dose of 2.5 mg/kg bw per day significantly reduced serum glucose, TC, TG, ALT, and AST levels,
and increased serum insulin levels, but there were no improvements in food–water intake and body weight change parameters
in lycopene-treated diabetic rats. The results suggest that orally administrated lycopene exhibits a potent hypoglycemic effect
in STZ-induced diabetic rats and that lycopene may be useful for the management of diabetes mellitus.
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INTRODUCTION
D iabetes is a severe disease caused by an autoimmunedestruction of pancreatic b-cells (type 1) or insulin re-
sistance (type 2). The concomitant hyperglycemia and/or
hypoinsulinemia have serious detrimental health effects and
often compromise the quality of life.1 Also, diabetes is as-
sociated with disturbances in carbohydrate, protein, and fat
metabolism that occurs secondary to an absolute or relative
lack of insulin (hypoinsulinemia).2
The goals of managing diabetes mellitus are to optimize
the control of blood glucose, to decrease the effects of
oxidative stress, and to normalize disturbances in lipid
metabolism.3
Synthetic antidiabetic agents used in the treatment of
diabetes can produce serious side effects, including hypo-
glycemic coma and impaired liver and kidney functions.
Therefore, the search for more effective and safer antidia-
betic agents continues to be an important area for research.4
For centuries, folk medicine has employed plants for their
medicinal and protective abilities. Recent epidemiologic
studies show that consumption of fruits, vegetables, grains,
and legumes prevents chronic illnesses. This has prompted
further research into herbal products with antidiabetic ac-
tivity possessing fewer side effects.5
Lycopene, a 40-carbon acyclic carotenoid with 11 line-
arly arranged conjugated double bonds,6 is a dietary carot-
enoid found in fruits, such as fresh ripe tomato, watermelon,
papaya, guava, and grapefruit, and is one of the primary
carotenoid components that accumulates in human tissues
and fluids, such as the prostate and serum, after absorption.7
Lycopene is a potent neuroprotective, antiproliferative,
anticancer, antiinflammatory, cognition enhancer, and hy-
pocholesterolemic agent.8 It has been ranked as being most
potent among the following antioxidants: lycopene > a-
tocopherol > a-carotene > b-cryptoxanthin > zeaxanthin = b-
carotene > lutein. Moreover, several studies suggest that
lycopene is a more potent scavenger of oxygen radicals
than any other major dietary carotenoids.9 Lycopene, be-
cause of its high number of conjugated double bonds, has
been reported to exhibit higher singlet-oxygen-quenching
ability compared with b-carotene or a-tocopherol and to
act as a potent antioxidant, preventing the oxidative
damage of critical biomolecules, including lipids, low-
density lipoproteins, proteins, and DNA.10,11 Lycopene
has been under considerable investigation for its antioxi-
dant benefits in treating various chronic human diseases,
like cancer, cardiovascular diseases, osteoporosis, and
diabetes.8
There is little information regarding the effects of lyco-
pene on diabetes. Therefore, in the present study, the effects
of lycopene, at a dose of 2.5 mg/kg body weight (bw), were
investigated in nondiabetic, diabetic, and lycopene-treated
diabetic rats. Accordingly, body weight changes, daily
food–water intake values, and serum glucose, insulin, total
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cholesterol (TC), triglyceride (TG), alanine aminotransfer-
ase (ALT), and aspartate aminotransferase (AST) levels
were measured and compared statically.
MATERIALS AND METHODS
Animals
Twenty-four adult Sprague–Dawley rats (weighing 190–
210 g) were obtained from TICAM (Medical and Surgical
Experimental Research Center, Eskisehir Osmangazi Uni-
versity) and housed in polycarbonate cages in an air-con-
ditioned room (22C – 2C) with a 12-h light/12-h dark
cycle (7:00 a.m. on; 7:00 p.m. off). Standard rat feed and
water were provided ad libitum. The rats were allowed to
acclimatize to the laboratory environment for 7 days before
the start of the experiment.
All procedures were conducted in conformity with the
Institutional Ethical Committee for Animal Care and Use at
Eskisehir Osmangazi University (protocol no. 26/158) and
the international guidelines on the ethical use of animals
(NIH publication no. 80-23).
Drug and reagents
Streptozotocin (STZ) and lycopene (catalogue nos.
S0130-1G and L9879-1 MG, respectively) were purchased
from Sigma.
Experimental induction of diabetes
Diabetes was induced following overnight fasting of the
rats by an intramuscular injection of STZ in a single dose of
50 mg/kg bw. STZ was dissolved in a freshly prepared 0.01 M
citrate buffer (pH 4.5) whereas the control rats were injected
with buffer alone. Five days after STZ administration, a di-
abetic state was confirmed by the positive response to glucose
presence in urine (urinalysis strips; Arkray).12
Experimental design
The rats were randomly divided into three groups as
follows (n = 8 per group): Group 1 (NC): nondiabetic control
rats; Group 2 (DC): diabetic control rats received vehicle
solution (olive oil, volume = 1 mL/kg bw); and Group 3
(LYCO): diabetic rats treated with lycopene 2.5 mg/kg bw
in vehicle solution.
The vehicle (olive oil, volume = 1 mL/kg bw) and the ly-
copene solutions (dissolved in olive oil, volume = 1 mL/kg bw)
were administered orally using an intragastric tube daily
for 7 days. At the same time, food–water intake and body
weight changes were recorded daily. After 7 days of treat-
ment, the rats were fasted overnight and then under
ether anesthesia, the blood samples from rats were in-
tracardiacly collected in polystyrene tubes without antico-
agulant. The rats were then immediately sacrificed by
cervical decapitation.
Biochemical analysis
The serum samples were separated by centrifugation at
1600 g at 4C for 15 min using a cooling centrifuge (Hermle
ZK510) and analyzed for the serum glucose, insulin, TC,
TG, ALT, AST.
The serum glucose, TC, TG, ALT, and AST levels were
immediately measured with a commercial kit (Biolabo)
using an autoanalyzer (Airone 200-RA; Crony Instruments).
The serum glucose, TC, and TG were expressed in mg/dL,
and ALT and AST were expressed in U/L.
Insulin assay
The serum insulin level of each blood sample was mea-
sured by an enzyme-linked immunosorbent assay using a
commercial kit (Ultrasensitive Rat Insulin Enzyme-Linked
Immunosorbent Assay; Mercodia), based on the direct sand-
wich technique in which two monoclonal antibodies are di-
rected against separate antigenic determinants on the insulin
molecule. The serum insulin levels were expressed as lg/L.
Statistical analyses
Results were expressed as mean – standard deviation. The
intergroup variations were measured by one-way analysis of
variance followed by Tukey’s test to assess the significance.
Statistical significance was considered at P < .05. The sta-
tistical analyses were performed using the SPSS Statistical
Software version 12.
RESULTS
Body weight (initial and final) and daily
food and water intake values
Table 1 shows the initial and final body weights and the
daily food and water intakes of all groups during the ex-
perimental period. There was slight decrease between initial
and final body weights in the DC and LYCO groups.







(g/100 g body weight)
Daily water intake
(mL/100 g body weight)
NC 197.75 – 3.45 204.50 – 2.77 7.23 – 0.42 16.63 – 1.79
DC 206.00 – 3.02 201.25 – 2.81 12.39 – 2.65a 47.12 – 2.94a
LYCO 204.00 – 2.61 201.50 – 5.83 11.09 – 2.50a 44.33 – 3.32a
Data are mean – standard deviation values (n = 8). For group descriptions, see ‘‘Materials and Methods’’ section.
aP < .05, significantly different from NC group by Tukey’s multiple range tests.
NC, nondiabetic control; DC, diabetic control; LYCO, diabetic treated with lycopene.
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The food and water intakes in the DC and LYCO groups
were significantly higher than in the NC group (P < .05). On
the other hand, food and water intakes were slightly, but not
significantly, higher in the lycopene-treated group as com-
pared with diabetic control group rats (Table 1).
Changes in serum glucose, insulin, TC, TG, ALT, and AST
STZ treatment caused significant increases in serum
glucose (485.01%), TC (61.23%), TG (66.84%), ALT
(95.66%), and AST (86.54%) and decreases in serum in-
sulin (291.59%) when compared with nondiabetic control
group (P < .05). In the LYCO-treated diabetic group, glu-
cose, insulin, TC, TG, ALT, and AST values were found to
be preserved (P < .05) compared with DC group. Although
administration of lycopene at the dose of 2.5 mg/kg bw per
day significantly reduced the serum glucose (18.21%), TC
(26.35%), TG (23.08%), ALT (31.28%), and AST
(25.65%) levels and increased the serum insulin level
(49.15%), the values were not restored to the same levels as
those of the normal control group after 7 days of treatment
(Table 2).
DISCUSSION
In research investigations, type 1 diabetes is usually in-
duced by an STZ injection and the animals often display
typical characteristics of diabetes, that is, polyuria, poly-
dipsia, increased water intake, dehydration, weight loss, and
increased food intake.1,13 The weight loss is associated with
abnormalities due to osmotic diuresis and glucose intoler-
ance, resulting from inadequate insulin secretion or hyper-
lipidemia in diabetes mellitus. Prolonged osmotic diuresis
may cause excessive urinary electrolyte loss. Disturbances
in renal function are associated with several abnormalities,
including proteinuria and progressive renal failure.14 The
present study is consistent with our earlier studies on dia-
betes with regard to body weight change and food–water
intake correlation between the nondiabetic and diabetic
control group.12,15,16 Generally, the body weights are re-
duced in STZ-induced diabetic rats and restored when
subjected to hypoglycemic treatment.17 In the present study,
unfortunately, there was no improvement in symptoms of
diabetes (body weight change and food–water intake) as a
result of treatment with lycopene (Table 1).
The mechanism by which STZ brings about its diabetic
state includes selective destruction of pancreatic b-cells that
makes cells less active, leading to poor sensitivity of insulin
for glucose uptake by tissues.18 Effective control of blood
glucose levels is a key step in preventing or reversing dia-
betic complications.15 Our findings clearly suggest that ly-
copene decreased the serum glucose and increased insulin
levels in STZ-induced diabetic rats (Table 2). Briefly, the
hypoglycemic effect of the lycopene can be explained by the
fact that it might have increased glucose utilization in dia-
betic rats by promoting insulin secretion in the pancreas.
Therefore, lycopene may have potential as an oral hypo-
glycemic agent in the control of diabetes mellitus.
Generally, following STZ treatment, the plasma AST and
ALT levels increase as a result of metabolic changes in the
liver, such as administration of toxin, cirrhosis of the liver,
hepatitis, and liver cancer. Thus, they can be used as
markers to assess the extent of liver damage.17 Epidemio-
logical studies show that diabetic patients are at higher risk
of chronic liver disease and hepatocellular carcinoma.
Diabetes and insulin resistance were also identified as im-
portant factors associated with an increased risk of advanced
liver fibrosis in patients with normal ALT.19 In diabetes,
several authors have reported increases in AST and ALT
activities as well as changes in lipid concentration in the
serum of diabetic patients.20 Moreover, AST (a nonspecific
marker for hepatic injury) and especially ALT (a specific
marker for hepatic parenchymal injury) are used in the
evaluation of hepatic disorders.20–22 An increase in these
enzyme activities reflects active liver damage18 and the in-
crease in the activities of plasma ALT and AST indicated
liver dysfunction. Ohaeri also found that liver was necro-
tized in STZ-induced diabetic rats.23 Therefore, an increase
in the activities of AST and ALT in plasma might be mainly
due to the leakage of these enzymes from the liver cytosol
into the blood stream.24 Injury to the hepatocytes alters their
transport function and membrane permeability, leading to
leakage of enzymes from the cells. Therefore, the marked
release of AST and ALT from liver cytosol into circulation
indicates severe damage to hepatic tissue membranes asso-
ciated with diabetes.25 Therefore, increased activities of
AST and ALT found in this study may be interpreted as a
result of the liver cell destruction or changes in the mem-
brane permeability, indicating that severe hepatocellular
damage is induced by diabetes.2 In the present study,
treatment with lycopene at the dose of 2.5 mg/kg bw per day
was able to protect against the increase in the activity of
these enzymes in diabetic rats (Table 2), demonstrating the
Table 2. Serum Glucose, Insulin, Total Cholesterol, Triglyceride, Alanine Aminotransferase,
and Aspartate Aminotransferase Values in Groups
Groups Glucose (mg/dL) Insulin (lg/L) TC (mg/dL) TG (mg/dL) ALT (U/L) AST (U/L)
NC 104.30 – 13.07 6.94 – 0.39 88.68 – 3.58 47.96 – 5.76 44.50 – 3.29 69.62 – 5.04
DC 505.87 – 19.88a 2.38 – 0.41a 142.98 – 10.66a 80.02 – 3.47a 87.07 – 9.33a 129.87 – 12.62a
LYCO 413.75 – 16.77ab 3.55 – 0.43ab 105.30 – 4.15ab 61.55 – 5.15ab 59.83 – 4.31ab 96.55 – 6.85ab
Data are mean – standard deviation values (n = 8).
P < .05, significantly different from aNC group and bDC group by Tukey’s multiple range tests.
TC, total cholesterol; TG, triglyceride; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
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protective effect of lycopene against diabetes-induced he-
patic damage, and suggesting it has potential as a hepato-
protective drug.
The liver and some other tissues participate in the up-
take, oxidation, and metabolic conversion of free fatty
acids; synthesis of cholesterol and phospholipids; and se-
cretion of specific classes of plasma lipoproteins, and the
liver is regarded as one of the central metabolic organs in
the body, regulating and maintaining lipid homeostasis.26
It has been demonstrated that insulin deficiency in diabetes
leads to a variety of derangements in metabolic and regu-
latory processes, which in turn lead to accumulation of
lipids in hepatic tissue.3 Also, it is known that diabetes is
usually associated with abnormally high levels of serum
lipids and it is associated with profound alterations in the
plasma lipid and lipoprotein profile.2 Accumulation of
lipids in diabetes is mediated through a variety of de-
rangements in metabolic and regulatory processes, espe-
cially insulin deficiency, thereby rendering the diabetic
patient more prone to hypercholesterolemia.27 In diabetes,
hypercholesterolemia is associated with the consequences
of hyperinsulinemia, insulin resistance, and glucose intol-
erance.28 Hypercholesterolemia and hypertriglyceridemia
in STZ-induced diabetic rats are well documented. Excess
production of serum fatty acids by STZ-induced diabetics
promotes the conversion of excess fatty acids into phos-
pholipids and cholesterol in liver.3 In addition, plasma TC
and TG levels are also strongly related to the degree of
diabetic control rats. The increased TC and TG levels ob-
served in diabetic rats may be the result of impaired liver
function, caused by the damage done by STZ, which acts
either directly or indirectly by enhancing the plasma glu-
cose levels.17 Generally, according to literature, improve-
ments in cholesterol and TG levels in the blood are
dependent upon the recovery of liver function. Further, the
recovery of liver function is dependent upon restoration of
blood glucose and insulin to more normal levels by treat-
ment of diabetes. These relationships explain our findings
clearly (Table 2) and our results suggest that lycopene
could be used as a drug to bring about both hypoglycemic
and hypolipidemic effects.
In conclusion, our results suggest that lycopene partially
reverses some diabetic complications. But, lycopene does
not show the expected impact on body weight change and
food–water intake after 7 days of treatment. However, Zhu
et al.29 reported that different doses of lycopene [10, 30, and
60 mg/(kg$day - 1), p.o.] are only expected to have an effect
on some STZ-induced diabetic symptoms after 30 days of
treatment. As might be expected from the study by Zhu
et al.,29 we believe that an increase in drug dose and/or
especially treatment duration might result in positive effect
of lycopene on body weight change and food–water intake
ratio. In accordance with the other parameters obtained in
the present study, we believe the data support that oral ad-
ministration of lycopene may have a potential benefit in
preventing diabetes, since pancreatic damage induced by
environmental chemicals and other factors is a cause of
diabetes.
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